Parabilis Medicines, Inc., formerly known as Cyclerion Therapeutics, Inc., is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of small-molecule therapeutics for people living with serious and orphan diseases. Parabilis leverages its deep expertise in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling pathway, specifically focusing on soluble guanylate cyclase (sGC) stimulators. These stimulators are designed to enhance the body's natural signaling to address various disease states. The company's lead therapeutic candidate, zagociguat, is a CNS-penetrant sGC stimulator currently being evaluated for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as other mitochondrial diseases where impaired signaling plays a critical role. Following its rebranding from Cyclerion in 2024, Parabilis continues to advance its clinical pipeline while seeking strategic opportunities to expand its portfolio. The company aims to address significant unmet medical needs by targeting the underlying biology of rare and debilitating conditions through precision pharmacology.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!